Business UpdateAug 7, 2026, 09:11 AM
Prenetics Global Completes Strategic Transformation, Secures $1B Funding
AI Summary
Prenetics Global Limited has completed a strategic transformation, divesting non-core assets including ACT Genomics, Europa 3PL Business, Insighta, and digital asset holdings, to focus entirely on its IM8 consumer health brand. The company secured up to $1 billion in growth financing from General Catalyst's Customer Value Fund for marketing spend and announced global ambassador partnerships with athletes and personalities like David Beckham, Lionel Messi, and Jay Shetty. This F-1/A filing registers 2,359,172 Class A Ordinary Shares for resale by selling shareholders, stemming from a warrant exchange program.
Key Highlights
- Secured up to $1 billion in growth financing from General Catalyst's Customer Value Fund.
- Divested ACT Genomics for up to ~$72M cash in October 2025.
- Divested Insighta for $70M cash in February 2026, with Tencent acquiring 35% equity stake.
- Divested full digital asset holdings for $41.3M proceeds in May 2026.
- Authorized a 12-month share repurchase program of up to $40M in March 2026.
- IM8 generated $60.1M revenue with approximately 63% gross margin in FY2025.
- Registered 2,359,172 Class A Ordinary Shares for resale by selling shareholders.
Price Impact
More from PRE